International Alliance for Biological Standardization
Latest Meeting Info:
IABS meeting Diagnostics in the Veterinary Field
Topic: Isothermal amplification methods for the detection and monitoring of infectious diseases – chances and limitations
Dr. Carsten Schroeder, Indical Bioscience, Germany
IABS Success Stories
See every IABS conferences since year 2000
If you would like to join IABS, click here to see the online and offline application form.
Upcoming events and News
May 15-17, 2019 - Wiesbaden, Germany
Registration Is Open!
Diagnostics in the Veterinary Field:
The Role in Health Surveillance and Disease Identification
Meeting objectives
Diagnostics are an essential tool to ensure the health of domestic and wild animals for both endemic and emerging diseases. They allow animal health professionals to understand and manage the general health status of domestic animals. They are also important tools to support public health initiatives in the case of zoonotic disease control. The meeting will provide an overview of existing systems and approaches / strategies for the use of diagnostics and to discuss the currently available diagnostics. The advantages / benefits and disadvantages / gaps of the current methods and methodologies will be identified and discussed. Proposals on how to increase the quality, efficacy, and utility of the existing strategies and methods and those under development will be made.
Registration and information about the meeting here
Scientific Committee
Sandra Blome, Friedrich Löffler Institut
Attila Farsang, CEVA
Cyril Gay, USDA
Richard Hill, IABS
Carmen Jungbäck, IABS, Chair
Vaughn Kubiak, Zoetis
Serge Leterme, IDEXX
David Mackay, EMA
Paul Midtlyng, University of Oslo
Egbert Mundt, Boehringer-Ingelheim
Amir Noormohammadi, University of Melbourne
Suelee Robbe-Austerman, APHIS-USDA
Sjaak de Wit, Deventer
September 25-26, 2019 - Bangkok, Thailand
Towards Rabies Elimination in Asia-Pacific – From Theory to Practice
Meeting objectives
The meeting aims at snowballing efforts and achieving substantial progress in rabies control in the Asia-Pacific region of the world in the near future. As the key focus is placed on canine rabies the meeting will be an important contribution to the initiative of the United Against Rabies collaboration of the World Health Organization (WHO), World Organisation for Animal Health (OIE), Food and Agriculture Organization of the United Nations (FAO), and Global Alliance for Rabies Control (GARC) of ending human dog-mediated rabies by 2030. Recognized international and local experts will give insights into state-of-the art intersectoral One Health approaches, standards, available tools and guidelines developed by international organizations and institutions and best-practice examples from the region on how to prevent human rabies by eliminating rabies at its animal source. As such the meeting provides a platform for health and veterinary services, managers of national and local rabies eliminations programs, researchers and other people interested in advancing knowledge of rabies surveillance, prevention and control, to meet each other, to share their experience and also to discuss challenges to overcome. The meeting is considered to be a starting point for a continuous professional exchange on the way to a rabies free Asia-Pacific.
Registration and information about the meeting here
Scientific Committee :
Dr Charung Muangchana Director, National Veterinary Institute, Thailand
Dr Karoon Chanachai, Department of Livestock Development (DLD), Thailand
Dr Thomas Müller, Chair Friedrich-Loeffler-Institut, Germany
Dr Conrad Freuling, Friedrich-Loeffler-Institut, Germany
Dr Bernadette Abela-Ridder, World Healandh Organization
Dr Ivana Knezevic, World Health Organization
Dr Gregorio Torres, World Organization for Animal Health (OIE)
Dr Katinka de Balogh, Food and Agricultural Organization of the UN (FAO)
Dr Carmen Jungbäck, International Alliance for Biological Standardization (IABS)
Dr Gowri Yale, Mission Rabies
Prof. Louis Nel,Global Alliance for Rabies Control
Dr Ryan Wallace, Centres for Disease Control and Prevention, USA
November 13-14, 2019 - Het Pand, University of Ghent, Belgium
2nd Next Generation Sequencing
for Adventitious Virus Detection
Meeting objectives
This meeting will focus on the current scientific data and knowledge related to the use of next generation sequencing technologies for adventitious virus detection in biological products. Discussions will include ongoing efforts and future needs toward standardization and validation of the technical and bioinformatics steps involved in NGS for its applications in characterization and safety evaluation of biologics, including human and animal vaccines. The meeting will bring together representatives from industry, academia, technology providers, and international regulatory bodies for developing a scientific consensus regarding readiness of NGS for detection of adventitious viruses in biologics.
Scientific Committee
Dieter Deforce, Ghent University / Federal Agency for Medicines and Health Products of Belgium (FAMHP)
Sebastiaan Theuns, Ghent University
Arifa Khan, U.S. Food and Drug Administration (FDA)
Pieter Neels, International Alliance for Biological Standardization (IABS)
Sven Arnouts, Ghent University / PROVAXS
Johannes Blümel, Paul-Ehrlich Institut (PEI)
Bill Egan, Novartis Vaccines & Diagnostics
Carmen Jungbäck, International Alliance for Biological Standardization (IABS)
Ivana Knezevic, World Heath Organization (WHO)
Laurent Mallet, Sanofi Pasteur
Gerald Schumann, Paul-Ehrlich Institut (PEI)
Joseph Victoria, Boehringer-Ingelheim
More information about this IABS-EU meeting coming soon...
December 3-4, 2019 - Bangkok, Thailand
SAVE THE DATE
Non-animal Testing of Vaccines - A Global Congress
Meeting objectives
IABS and Vac2Vac are honoured to be organizing a Global Congress that will focus on replacement of in vivo testing of vaccines by in vitro methods with utilization of new and improved technologies. Progresses made with analytical tools and their applications have contributed to development of fast, precise and highly reliable in vitro tests that will allow batch to batch release of vaccines by consistency approach. Recent case studies on specific vaccines will be reviewed, and ongoing as well as future studies on other vaccines will be discussed. A particular emphasis will be placed on global coordination in areas of manufacturing and testing practices, and regulatory acceptance, with the goal of reducing time to market and increasing global access to vaccines. Participation from all of these areas of vaccine development, especially from LMICs and GAVI countries, is strongly encouraged. Bangkok has been selected as the site for this Congress because of its location amid countries with emerging vaccine producers and growing needs for vaccines.
We are honoured to have pledges of support from global foundations and partners from emerging economies.
More information coming soon....
February 6-7, 2020 - Pembroke College - Oxford, United Kingdom
SAVE THE DATE
3rd Human Challenge Trials in Vaccine Development
More information about this meeting soon....
October 22, 2019 - Paul-Ehrlich-Institut, Langen, Germany
SAVE THE DATE
Quality of Challenge Agent
An IABS-EU Meeting
Meeting Objectives
One of the proposed tools for faster development of new vaccines is CHIM: Controlled Human Infectious Models. These models can be used for early PoC (Proof of Concept) and as a basis for clinical “Go/No Go” decisions, in particular if sporadic epidemiology impedes clinical development.
In these models researchers will use a challenge agent: a virus, bacterium or parasite. Frequently questions are raised on the quality of the agent. Should this agent be produced following GMP? What strain-related information is relevant? Should it be attentuated or resemble the wild type?
These questions will be discussed during this symposium, more information will follow soon
In Brief
-
Welcome message from the President
Dear Colleagues
It is a pleasure to announce another milestone in the distinguished history of the International Alliance for Biological Standardization (IABS); the hiring of an Executive Director. For the first time in the 64-year history of IABS, the Board of Directors established an executive position to help oversee IABS operations.
I am pleased to announce that on March 1, 2019 Mr. Phillippe Sabot started his tenure as the first IABS Executive Director.
-
NICEATM / IABS 3Rs meeting - NIH, Bethesda, Maryland
Implementing non-animal approaches to human and veterinary vaccine testing:
Achieving scientific and regulatory success for rabies and beyondView the meeting webpage Here
- 1
Latest news
-
View the speaker slides from the 3Rs meeting, NIH, Bethesda : folder click here
View the meeting webpage Here
-
IABS Presentation to the U.S. Veterinary Biologics Training Program
In May 2018, an overview of IABS’ mission and activities was presented at the U.S. Veterinary Biologics Training Program. The training program is co-sponsored by the USDA APHIS Center for Veterinary Biologics, the USDA APHIS National Veterinary Services Laboratories and the ISU College of Veterinary Medicine’s Institute for International Cooperation in Animal Biologics (IICAB). The IICAB was founded in 1995 by the USDA Animal and Plant Health Inspection Service and Iowa State University. In June 1998, the IICAB received designation as a component of the World Organization for Animal Health (OIE) Collaborating Centre for the Diagnosis of Animal Diseases and Vaccine Evaluation in the Americas. The designation is shared with the USDA APHIS National Veterinary Services Laboratories (NVSL) and Center for Veterinary Biologics (CVB).
The first Veterinary Biologics Training Program was held in June 1996 at the ISU College of Veterinary Medicine. The training program has been offered each year since then. More than 2600 individuals have attended the program including over 740 international participants from 90 different countries. More than 150 participants attended in 2018. The program is known worldwide as a premier training program in immunology and veterinary vaccines. Many individuals who have participated in the training continue to be actively involved with veterinary biologics issues and activities world-wide.
Training Program participants were keenly interested in IABS and had many questions. Complimentary IABS Membership for 2018-2019 was offered to participants. IABS is looking forward to some of the new members attending upcoming conferences and workshops and becoming more actively involved with our organization.
Respectfully submitted,
Rick Hill, IABS Communication Committee Chair
-
Join CASSS for the first CASSS Cell & Gene Therapy Products meeting on July 10-12, 2018 at the Bethesda North Marriott Hotel & Conference Center, Rockville, MD.
We are very pleased to be launching the Symposium this July, continuing CASSS’ commitment to driving science forward and pushing through pre-conceived notions.
Learn more at http://www.casss.org/?page=CGTP1801
-
IABS “3R” Conferences Highlighted in Presentation at the 10th World Congress on Alternatives and Animal Use in the Life Sciences.
August 24, 2017, an overview of IABS’ “3R” Conferences, Symposia and Workshops was included in a presentation at the vaccine session at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle Washington (See Summary Slide below). The World Congress are periodic scientific meetings with emphasis on the latest technologies for reduction and replacement of animals and innovations in approaches to ethics, animal welfare and public policy. Interestingly, the World Congress’ first meeting was in 1993, within one year of the IABS’s first Langen Symposium. The 11th World Congress is scheduled for 2020 in the Netherlands.
In general, World Congress participants were aware of IABS’ leadership in the “3R” and Animal “Alternatives” arena and several inquired about the status of future IABS conferences. The meeting presented an opportunity to discuss IABS overall, but also the organizations strategic priority to host “3R” related meetings by the North American and European Affiliates.
Respectfully submitted,
Rick Hill, IABS Communication Committee Chair
-
IABS is pleased to announce a valuable new book written by Board Member Dr. Rebecca Sheets titled Fundamentals of Biologicals Regulation: Vaccines & Biotechnology Medicines. Dec. 2017, published by Elsevier’s imprint Academic Press.
For more information, please see https://www.elsevier.com/books/fundamentals-of-biologicals-regulation/sheets/978-0-12-809290-3
- 1
- 2
- 3
- 4
- 5
IABS-EU Heads Work Package in new IMI project: VAC2VAC
VAV2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The initiative that started on 1 March 2016 aims to provide the data to support the "Consistency Approach" for quality control of established vaccines, where current quality control approaches are often relying on in vivo methods.
VAC2VAC is a public-private consortium of twenty partners, involving experts from veterinary and human vaccine industry in a partnership with official medicines control laboratories, academia, translational research organisations, and vaccinology alliances. To achieve their goal, the project partners will develop, optimise and evaluate physico-chemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies. The ultimate goal of the project is to develop tests and approaches that will allow acceptance of the "Consistency Approach" for established vaccines by the regulatory agencies and thereby significantly reducing in the future the use of animals for batch testing in routine vaccine production.
ZAPI
About ZAPI - The new Zoonoses Anticipation and Preparedness Initiative (ZAPI), part of the Innovative Medicines Initiative (IMI) public-private partnership, aims to enable swift response to major new infectious disease threats in Europe and throughout the world by designing new manufacturing processes (up to large scale) for delivering effective control tools (vaccines, antibodies/antibody-like molecules) against (re-)emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases…
IABS-EU is officially recognized by French authorities as a nonprofit organization.
You will be hearing more about IABS-EU in the months ahead.
|
Founding Members :
|
Read more: |
Twitter Feed
Contact Info
CH-1204 Geneva
Switzerland